Thirdly, we did not carry out subgroup analyses according to tumor stage, oncogenic alteration (e.g., EGFR mutation, EML4-ALK fusion, KRAS mutation), expression status of PD-1/PD-L1, etc. due to the limitations of the data. The gene discussed is ALK; the disease is neoplasm.